Publications

BibTex format

@article{Lythgoe:2021:10.1016/j.drudis.2020.11.011,
author = {Lythgoe, MP and Krell, J and Mahmoud, S and Mills, E and Vasudevan, A and Savage, P},
doi = {10.1016/j.drudis.2020.11.011},
journal = {Drug Discovery Today},
pages = {301--307},
title = {Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019},
url = {http://dx.doi.org/10.1016/j.drudis.2020.11.011},
volume = {26},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Analysis of new anticancer drugs licensed in the UK found that 44 new therapies were approved from 2015 to 2019. No other 5-year period has produced as many new therapies. Most new drugs are kinase inhibitors (KIs, N = 18) and monoclonal antibodies (mAbs, N = 16) with only one classical cytotoxic chemotherapy (CC) licensed. The average median treatment duration has risen by 55 days to 318 days (263 days in 2010–2014). Drug costs have escalated; an average treatment course now costs £62 343, compared to £35 383 in 2010–2014. New drugs are delivering significant clinical benefits with longer treatment durations. However, the financial burden is greater, heralding economic challenges for healthcare providers.
AU  - Lythgoe,MP
AU  - Krell,J
AU  - Mahmoud,S
AU  - Mills,E
AU  - Vasudevan,A
AU  - Savage,P
DO  - 10.1016/j.drudis.2020.11.011
EP  - 307
PY  - 2021///
SN  - 1359-6446
SP  - 301
TI  - Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019
T2  - Drug Discovery Today
UR  - http://dx.doi.org/10.1016/j.drudis.2020.11.011
UR  - https://www.sciencedirect.com/science/article/pii/S1359644620304773?via%3Dihub
UR  - http://hdl.handle.net/10044/1/84183
VL  - 26
ER  -

Download

DrJonathanKrell

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)